ABCA3_HUMAN
ID ABCA3_HUMAN Reviewed; 1704 AA.
AC Q99758; B2RU09; Q54A95; Q6P5P9; Q92473;
DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT 24-JAN-2006, sequence version 2.
DT 03-AUG-2022, entry version 185.
DE RecName: Full=Phospholipid-transporting ATPase ABCA3 {ECO:0000305};
DE EC=7.6.2.1 {ECO:0000269|PubMed:17574245, ECO:0000269|PubMed:28887056, ECO:0000269|PubMed:31473345};
DE AltName: Full=ABC-C transporter;
DE AltName: Full=ATP-binding cassette sub-family A member 3 {ECO:0000305};
DE AltName: Full=ATP-binding cassette transporter 3;
DE Short=ATP-binding cassette 3;
DE AltName: Full=Xenobiotic-transporting ATPase ABCA3 {ECO:0000305};
DE EC=7.6.2.2 {ECO:0000305|PubMed:26903515};
DE Contains:
DE RecName: Full=150 Kda mature form {ECO:0000305|PubMed:27031696};
GN Name=ABCA3 {ECO:0000312|HGNC:HGNC:33}; Synonyms=ABC3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC TISSUE=Thyroid carcinoma;
RX PubMed=8706931; DOI=10.1016/0014-5793(96)00700-4;
RA Klugbauer N., Hofmann F.;
RT "Primary structure of a novel ABC transporter with a chromosomal
RT localization on the band encoding the multidrug resistance-associated
RT protein.";
RL FEBS Lett. 391:61-65(1996).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=9027511; DOI=10.1006/geno.1996.4500;
RA Connors T.D., van Raay T.J., Petry L.R., Klinger K.W., Landes G.M.,
RA Burn T.C.;
RT "The cloning of a human ABC gene (ABC3) mapping to chromosome 16p13.3.";
RL Genomics 39:231-234(1997).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND SUBCELLULAR
RP LOCATION.
RC TISSUE=Lung;
RX PubMed=11718719; DOI=10.1016/s0014-5793(01)03056-3;
RA Yamano G., Funahashi H., Kawanami O., Zhao L., Ban N., Uchida Y.,
RA Morohoshi T., Ogawa J., Shioda S., Inagaki N.;
RT "ABCA3 is a lamellar body membrane protein in human lung alveolar type II
RT cells.";
RL FEBS Lett. 508:221-225(2001).
RN [4]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-140 AND SER-766.
RG SeattleSNPs variation discovery resource;
RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15616553; DOI=10.1038/nature03187;
RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA Myers R.M., Rubin E.M., Pennacchio L.A.;
RT "The sequence and analysis of duplication-rich human chromosome 16.";
RL Nature 432:988-994(2004).
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC TISSUE=Brain, and Lung;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [8]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-197, AND SUBCELLULAR LOCATION.
RX PubMed=22673903; DOI=10.1038/ncomms1871;
RA Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA Olsen J.V.;
RT "Quantitative maps of protein phosphorylation sites across 14 different rat
RT organs and tissues.";
RL Nat. Commun. 3:876-876(2012).
RN [9]
RP FUNCTION, PROTEOLYTIC CLEAVAGE, GLYCOSYLATION, SUBCELLULAR LOCATION,
RP CHARACTERIZATION OF VARIANTS SMDP3 PRO-101; ASP-568; PRO-982; SER-1221;
RP PRO-1553; PRO-1580 AND PRO-1591, AND MUTAGENESIS OF GLY-1221 AND LEU-1580.
RX PubMed=16959783; DOI=10.1074/jbc.m600071200;
RA Matsumura Y., Ban N., Ueda K., Inagaki N.;
RT "Characterization and classification of ATP-binding cassette transporter
RT ABCA3 mutants in fatal surfactant deficiency.";
RL J. Biol. Chem. 281:34503-34514(2006).
RN [10]
RP FUNCTION, CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANT SMDP3 ASP-568,
RP AND SUBCELLULAR LOCATION.
RX PubMed=17574245; DOI=10.1016/j.febslet.2007.05.078;
RA Matsumura Y., Sakai H., Sasaki M., Ban N., Inagaki N.;
RT "ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in
RT A549 cells.";
RL FEBS Lett. 581:3139-3144(2007).
RN [11]
RP PROTEOLYTIC CLEAVAGE, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP VARIANTS SMDP3 LYS-215 AND VAL-292.
RX PubMed=20863830; DOI=10.1016/j.febslet.2010.09.026;
RA Engelbrecht S., Kaltenborn E., Griese M., Kern S.;
RT "The surfactant lipid transporter ABCA3 is N-terminally cleaved inside
RT LAMP3-positive vesicles.";
RL FEBS Lett. 584:4306-4312(2010).
RN [12]
RP GLYCOSYLATION AT ASN-124 AND ASN-140, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP OF ASN-53; ASN-124; ASN-140 AND ASN-945.
RX PubMed=24142515; DOI=10.1152/ajplung.00184.2013;
RA Beers M.F., Zhao M., Tomer Y., Russo S.J., Zhang P., Gonzales L.W.,
RA Guttentag S.H., Mulugeta S.;
RT "Disruption of N-linked glycosylation promotes proteasomal degradation of
RT the human ATP-binding cassette transporter ABCA3.";
RL Am. J. Physiol. 305:L970-L980(2013).
RN [13]
RP FUNCTION, CHARACTERIZATION OF VARIANTS SMDP3 LYS-215 AND VAL-292, AND
RP CATALYTIC ACTIVITY.
RX PubMed=25817392; DOI=10.1016/j.bbalip.2015.03.004;
RA Zarbock R., Kaltenborn E., Frixel S., Wittmann T., Liebisch G., Schmitz G.,
RA Griese M.;
RT "ABCA3 protects alveolar epithelial cells against free cholesterol induced
RT cell death.";
RL Biochim. Biophys. Acta 1851:987-995(2015).
RN [14]
RP SUBUNIT, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS SMDP3 LYS-215;
RP CYS-280 AND LYS-288, AND MUTAGENESIS OF SER-693.
RX PubMed=27352740; DOI=10.3892/ijmm.2016.2650;
RA Frixel S., Lotz-Havla A.S., Kern S., Kaltenborn E., Wittmann T.,
RA Gersting S.W., Muntau A.C., Zarbock R., Griese M.;
RT "Homooligomerization of ABCA3 and its functional significance.";
RL Int. J. Mol. Med. 38:558-566(2016).
RN [15]
RP INDUCTION, FUNCTION, AND CATALYTIC ACTIVITY.
RX PubMed=26903515; DOI=10.1074/jbc.m115.688168;
RA Dohmen L.C., Navas A., Vargas D.A., Gregory D.J., Kip A., Dorlo T.P.,
RA Gomez M.A.;
RT "Functional Validation of ABCA3 as a Miltefosine Transporter in Human
RT Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA)
RT PANAMENSIS.";
RL J. Biol. Chem. 291:9638-9647(2016).
RN [16]
RP IDENTIFICATION BY MASS SPECTROMETRY, PROTEOLYTIC CLEAVAGE, SITE, AND
RP MUTAGENESIS OF 173-LEU-LYS-174.
RX PubMed=27031696; DOI=10.1371/journal.pone.0152594;
RA Hofmann N., Galetskiy D., Rauch D., Wittmann T., Marquardt A., Griese M.,
RA Zarbock R.;
RT "Analysis of the Proteolytic Processing of ABCA3: Identification of
RT Cleavage Site and Involved Proteases.";
RL PLoS ONE 11:e0152594-e0152594(2016).
RN [17]
RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS SMDP3
RP VAL-292 AND ASN-1388.
RX PubMed=28887056; DOI=10.1016/j.bbamcr.2017.08.013;
RA Hoeppner S., Kinting S., Torrano A.A., Schindlbeck U., Braeuchle C.,
RA Zarbock R., Wittmann T., Griese M.;
RT "Quantification of volume and lipid filling of intracellular vesicles
RT carrying the ABCA3 transporter.";
RL Biochim. Biophys. Acta 1864:2330-2335(2017).
RN [18]
RP CATALYTIC ACTIVITY, FUNCTION, SUBCELLULAR LOCATION, CHARACTERIZATION OF
RP VARIANTS SMDP3 ASP-568 AND PRO-1580, AND ACTIVITY REGULATION.
RX PubMed=31473345; DOI=10.1016/j.bbalip.2019.158516;
RA Li Y., Kinting S., Hoeppner S., Forstner M.E., Uhl O., Koletzko B.,
RA Griese M.;
RT "Metabolic labelling of choline phospholipids probes ABCA3 transport in
RT lamellar bodies.";
RL Biochim. Biophys. Acta 1864:158516-158516(2019).
RN [19]
RP VARIANTS SMDP3 PRO-101; ASP-568; PRO-982; SER-1221; PRO-1553; PRO-1580 AND
RP PRO-1591.
RX PubMed=15044640; DOI=10.1056/nejmoa032178;
RA Shulenin S., Nogee L.M., Annilo T., Wert S.E., Whitsett J.A., Dean M.;
RT "ABCA3 gene mutations in newborns with fatal surfactant deficiency.";
RL N. Engl. J. Med. 350:1296-1303(2004).
RN [20]
RP VARIANTS SMDP3 VAL-292; LYS-690; LYS-1076; MET-1114; LEU-1301 AND GLU-1302.
RX PubMed=15976379; DOI=10.1164/rccm.200503-504oc;
RA Bullard J.E., Wert S.E., Whitsett J.A., Dean M., Nogee L.M.;
RT "ABCA3 mutations associated with pediatric interstitial lung disease.";
RL Am. J. Respir. Crit. Care Med. 172:1026-1031(2005).
RN [21]
RP VARIANTS SMDP3 LEU-43; LYS-215; PRO-579; GLN-605 AND 1561-ARG--ARG-1704
RP DEL, AND VARIANT LYS-288.
RX PubMed=16728712; DOI=10.1164/rccm.200509-1535oc;
RA Brasch F., Schimanski S., Muehlfeld C., Barlage S., Langmann T.,
RA Aslanidis C., Boettcher A., Dada A., Schroten H., Mildenberger E.,
RA Prueter E., Ballmann M., Ochs M., Johnen G., Griese M., Schmitz G.;
RT "Alteration of the pulmonary surfactant system in full-term infants with
RT hereditary ABCA3 deficiency.";
RL Am. J. Respir. Crit. Care Med. 174:571-580(2006).
RN [22]
RP VARIANTS [LARGE SCALE ANALYSIS] MET-290; ASP-801 AND GLN-1069.
RX PubMed=16959974; DOI=10.1126/science.1133427;
RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA Velculescu V.E.;
RT "The consensus coding sequences of human breast and colorectal cancers.";
RL Science 314:268-274(2006).
RN [23]
RP VARIANTS SMDP3 CYS-280; MET-1399 AND 1589-GLN--ARG-1704 DEL.
RX PubMed=25712598; DOI=10.1038/jp.2014.236;
RA Jackson T., Wegner D.J., White F.V., Hamvas A., Cole F.S., Wambach J.A.;
RT "Respiratory failure in a term infant with cis and trans mutations in
RT ABCA3.";
RL J. Perinatol. 35:231-232(2015).
RN [24]
RP VARIANT SMDP3 ASN-1388, CHARACTERIZATION OF VARIANT SMDP3 ASN-1388,
RP PROTEOLYTIC CLEAVAGE, GLYCOSYLATION, SUBCELLULAR LOCATION, FUNCTION, AND
RP CATALYTIC ACTIVITY.
RX PubMed=27177387; DOI=10.1002/ppul.23471;
RA Wittmann T., Schindlbeck U., Hoeppner S., Kinting S., Frixel S.,
RA Kroener C., Liebisch G., Hegermann J., Aslanidis C., Brasch F., Reu S.,
RA Lasch P., Zarbock R., Griese M.;
RT "Tools to explore ABCA3 mutations causing interstitial lung disease.";
RL Pediatr. Pulmonol. 51:1284-1294(2016).
CC -!- FUNCTION: Catalyzes the ATP-dependent transport of phospholipids such
CC as phosphatidylcholine and phosphoglycerol from the cytoplasm into the
CC lumen side of lamellar bodies, in turn participates in the lamellar
CC bodies biogenesis and homeostasis of pulmonary surfactant
CC (PubMed:16959783, PubMed:17574245, PubMed:28887056, PubMed:31473345,
CC PubMed:27177387). Transports preferentially phosphatidylcholine
CC containing short acyl chains (PubMed:27177387). In addition plays a
CC role as an efflux transporter of miltefosine across macrophage
CC membranes and free cholesterol (FC) through intralumenal vesicles by
CC removing FC from the cell as a component of surfactant and protects
CC cells from free cholesterol toxicity (PubMed:26903515, PubMed:25817392,
CC PubMed:27177387). {ECO:0000269|PubMed:16959783,
CC ECO:0000269|PubMed:17574245, ECO:0000269|PubMed:25817392,
CC ECO:0000269|PubMed:26903515, ECO:0000269|PubMed:27177387,
CC ECO:0000269|PubMed:28887056, ECO:0000269|PubMed:31473345}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + H2O + xenobioticSide 1 = ADP + phosphate +
CC xenobioticSide 2.; EC=7.6.2.2;
CC Evidence={ECO:0000305|PubMed:26903515};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine(in) + ATP + H2O = a
CC 1,2-diacyl-sn-glycero-3-phosphocholine(out) + ADP + H(+) + phosphate;
CC Xref=Rhea:RHEA:66272, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, ChEBI:CHEBI:57643,
CC ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:17574245,
CC ECO:0000269|PubMed:27177387, ECO:0000269|PubMed:28887056,
CC ECO:0000269|PubMed:31473345};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66273;
CC Evidence={ECO:0000269|PubMed:17574245, ECO:0000269|PubMed:27177387,
CC ECO:0000269|PubMed:28887056, ECO:0000269|PubMed:31473345};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + H2O + phospholipidSide 1 = ADP + phosphate +
CC phospholipidSide 2.; EC=7.6.2.1;
CC Evidence={ECO:0000269|PubMed:17574245, ECO:0000269|PubMed:27177387,
CC ECO:0000269|PubMed:28887056, ECO:0000269|PubMed:31473345};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine(in) + ATP + H2O
CC = 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine(out) + ADP + H(+) +
CC phosphate; Xref=Rhea:RHEA:66340, ChEBI:CHEBI:15377,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC ChEBI:CHEBI:72999, ChEBI:CHEBI:456216;
CC Evidence={ECO:0000269|PubMed:27177387};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66341;
CC Evidence={ECO:0000269|PubMed:27177387};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + cholesterol(in) + H2O = ADP + cholesterol(out) + H(+) +
CC phosphate; Xref=Rhea:RHEA:39051, ChEBI:CHEBI:15377,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:16113, ChEBI:CHEBI:30616,
CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC Evidence={ECO:0000269|PubMed:25817392};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39052;
CC Evidence={ECO:0000269|PubMed:25817392};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)(in) + ATP +
CC H2O = 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)(out) + ADP +
CC H(+) + phosphate; Xref=Rhea:RHEA:66344, ChEBI:CHEBI:15377,
CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC ChEBI:CHEBI:64716, ChEBI:CHEBI:456216;
CC Evidence={ECO:0000250|UniProtKB:Q8R420};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66345;
CC Evidence={ECO:0000250|UniProtKB:Q8R420};
CC -!- ACTIVITY REGULATION: The ATP-dependent phosphatidylcholine transport is
CC competitively inhibited by miltefosine. {ECO:0000269|PubMed:31473345}.
CC -!- SUBUNIT: Homooligomer; disulfide-linked. {ECO:0000269|PubMed:31473345}.
CC -!- SUBCELLULAR LOCATION: Endosome, multivesicular body membrane
CC {ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:20863830,
CC ECO:0000269|PubMed:27177387}; Multi-pass membrane protein
CC {ECO:0000305}. Cytoplasmic vesicle membrane
CC {ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:17574245,
CC ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:22673903,
CC ECO:0000269|PubMed:27177387, ECO:0000269|PubMed:31473345}. Late
CC endosome membrane {ECO:0000269|PubMed:27177387}. Lysosome membrane
CC {ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:17574245,
CC ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:24142515}.
CC Note=Localized in the limiting membrane of lamellar bodies in lung
CC alveolar type II cells (PubMed:22673903, PubMed:16959783,
CC PubMed:24142515, PubMed:27177387, PubMed:11718719). Trafficks via the
CC Golgi, sorting vesicles (SVs) and late endosome/multivesicular body
CC network directly to the outer membrane of lamellar bodies in AT2 lung
CC epithelial cells or to lysosomes and lysosomal-related organelles
CC (LROs) in other cells where undergoes proteolytic cleveage and
CC oligosaccharide processing from high mannose type to complex type
CC (PubMed:24142515, PubMed:20863830, PubMed:16959783, PubMed:27177387).
CC Oligomers formation takes place in a post-endoplasmic reticulum
CC compartment (PubMed:27352740). {ECO:0000269|PubMed:11718719,
CC ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:20863830,
CC ECO:0000269|PubMed:22673903, ECO:0000269|PubMed:24142515,
CC ECO:0000269|PubMed:27177387, ECO:0000269|PubMed:27352740}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=Q99758-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q99758-2; Sequence=VSP_056262, VSP_056263;
CC -!- TISSUE SPECIFICITY: Expressed in brain, pancreas, skeletal muscle and
CC heart (PubMed:8706931). Highly expressed in the lung in an AT2-cell-
CC specific manner (PubMed:11718719, PubMed:8706931). Weakly expressed in
CC placenta, kidney and liver (PubMed:8706931). Also expressed in
CC medullary thyroid carcinoma cells (MTC) and in C-cell carcinoma
CC (PubMed:8706931). {ECO:0000269|PubMed:11718719,
CC ECO:0000269|PubMed:8706931}.
CC -!- INDUCTION: Up-regulated in Leishmania Viannia (L.V.) panamensis-
CC infected macrophages exposed to miltefosine (PubMed:26903515). Down-
CC regulated by L. V. panamensis infection (PubMed:26903515).
CC {ECO:0000269|PubMed:26903515}.
CC -!- DOMAIN: Multifunctional polypeptide with two homologous halves, each
CC containing a hydrophobic membrane-anchoring domain and an ATP binding
CC cassette (ABC) domain. {ECO:0000250}.
CC -!- PTM: N-glycosylated (PubMed:16959783, PubMed:24142515,
CC PubMed:27177387). Localization at intracellular vesicles is accompanied
CC by processing of oligosaccharide from high mannose type to complex type
CC (PubMed:16959783, PubMed:27177387). N-linked glycosylation at Asn-124
CC and Asn-140 is required for stability and efficient anterograde
CC trafficking and prevents from proteasomal degradation
CC (PubMed:24142515). {ECO:0000269|PubMed:16959783,
CC ECO:0000269|PubMed:24142515, ECO:0000269|PubMed:27177387}.
CC -!- PTM: Proteolytically cleaved by CTSL and to a lower extent by CTSB
CC within multivesicular bodies (MVB) and lamellar bodies (LB) leading to
CC a mature form of 150 kDa. {ECO:0000269|PubMed:16959783,
CC ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:27031696,
CC ECO:0000269|PubMed:27177387}.
CC -!- DISEASE: Pulmonary surfactant metabolism dysfunction 3 (SMDP3)
CC [MIM:610921]: A rare lung disorder due to impaired surfactant
CC homeostasis. It is characterized by alveolar filling with floccular
CC material that stains positive using the periodic acid-Schiff method and
CC is derived from surfactant phospholipids and protein components.
CC Excessive lipoproteins accumulation in the alveoli results in severe
CC respiratory distress. {ECO:0000269|PubMed:15044640,
CC ECO:0000269|PubMed:15976379, ECO:0000269|PubMed:16728712,
CC ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:17574245,
CC ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:25712598,
CC ECO:0000269|PubMed:25817392, ECO:0000269|PubMed:27177387,
CC ECO:0000269|PubMed:27352740, ECO:0000269|PubMed:28887056,
CC ECO:0000269|PubMed:31473345}. Note=The disease is caused by variants
CC affecting the gene represented in this entry.
CC -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCA family.
CC {ECO:0000305}.
CC -!- WEB RESOURCE: Name=SeattleSNPs;
CC URL="http://pga.gs.washington.edu/data/abca3/";
CC -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC proteins;
CC URL="http://abcm2.hegelab.org/search";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U78735; AAC50967.1; -; mRNA.
DR EMBL; X97187; CAA65825.1; -; mRNA.
DR EMBL; AB070929; BAB86781.1; -; mRNA.
DR EMBL; DQ073080; AAY57325.1; -; Genomic_DNA.
DR EMBL; CH471112; EAW85515.1; -; Genomic_DNA.
DR EMBL; BC020724; AAH20724.1; -; mRNA.
DR EMBL; BC062779; AAH62779.1; -; mRNA.
DR EMBL; AC009065; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AC098805; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AC106820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC140895; AAI40896.1; -; mRNA.
DR EMBL; BC146866; AAI46867.1; -; mRNA.
DR CCDS; CCDS10466.1; -. [Q99758-1]
DR PIR; A59188; A59188.
DR PIR; S71363; S71363.
DR RefSeq; NP_001080.2; NM_001089.2. [Q99758-1]
DR AlphaFoldDB; Q99758; -.
DR SMR; Q99758; -.
DR BioGRID; 106539; 46.
DR IntAct; Q99758; 20.
DR MINT; Q99758; -.
DR STRING; 9606.ENSP00000301732; -.
DR DrugBank; DB00619; Imatinib.
DR TCDB; 3.A.1.211.5; the atp-binding cassette (abc) superfamily.
DR GlyGen; Q99758; 6 sites.
DR iPTMnet; Q99758; -.
DR PhosphoSitePlus; Q99758; -.
DR BioMuta; ABCA3; -.
DR DMDM; 85700402; -.
DR jPOST; Q99758; -.
DR MassIVE; Q99758; -.
DR MaxQB; Q99758; -.
DR PaxDb; Q99758; -.
DR PeptideAtlas; Q99758; -.
DR PRIDE; Q99758; -.
DR ProteomicsDB; 66998; -.
DR ProteomicsDB; 78463; -. [Q99758-1]
DR Antibodypedia; 1409; 78 antibodies from 19 providers.
DR DNASU; 21; -.
DR Ensembl; ENST00000301732.10; ENSP00000301732.5; ENSG00000167972.14. [Q99758-1]
DR Ensembl; ENST00000567910.1; ENSP00000454397.1; ENSG00000167972.14. [Q99758-2]
DR GeneID; 21; -.
DR KEGG; hsa:21; -.
DR MANE-Select; ENST00000301732.10; ENSP00000301732.5; NM_001089.3; NP_001080.2.
DR UCSC; uc002cpy.2; human. [Q99758-1]
DR CTD; 21; -.
DR DisGeNET; 21; -.
DR GeneCards; ABCA3; -.
DR HGNC; HGNC:33; ABCA3.
DR HPA; ENSG00000167972; Tissue enhanced (lung).
DR MalaCards; ABCA3; -.
DR MIM; 601615; gene.
DR MIM; 610921; phenotype.
DR neXtProt; NX_Q99758; -.
DR OpenTargets; ENSG00000167972; -.
DR Orphanet; 2032; Idiopathic pulmonary fibrosis.
DR Orphanet; 70587; Infant acute respiratory distress syndrome.
DR Orphanet; 440402; Interstitial lung disease due to ABCA3 deficiency.
DR PharmGKB; PA24378; -.
DR VEuPathDB; HostDB:ENSG00000167972; -.
DR eggNOG; KOG0059; Eukaryota.
DR GeneTree; ENSGT00940000155289; -.
DR HOGENOM; CLU_113155_0_0_1; -.
DR InParanoid; Q99758; -.
DR OMA; WKNWIVL; -.
DR PhylomeDB; Q99758; -.
DR TreeFam; TF105191; -.
DR PathwayCommons; Q99758; -.
DR Reactome; R-HSA-1369062; ABC transporters in lipid homeostasis.
DR Reactome; R-HSA-5683678; Defective ABCA3 causes SMDP3.
DR Reactome; R-HSA-5683826; Surfactant metabolism.
DR Reactome; R-HSA-5688399; Defective ABCA3 causes SMDP3.
DR SignaLink; Q99758; -.
DR SIGNOR; Q99758; -.
DR BioGRID-ORCS; 21; 16 hits in 1078 CRISPR screens.
DR ChiTaRS; ABCA3; human.
DR GeneWiki; ABCA3; -.
DR GenomeRNAi; 21; -.
DR Pharos; Q99758; Tbio.
DR PRO; PR:Q99758; -.
DR Proteomes; UP000005640; Chromosome 16.
DR RNAct; Q99758; protein.
DR Bgee; ENSG00000167972; Expressed in lower lobe of lung and 145 other tissues.
DR ExpressionAtlas; Q99758; baseline and differential.
DR Genevisible; Q99758; HS.
DR GO; GO:0097208; C:alveolar lamellar body; IDA:MGI.
DR GO; GO:0097233; C:alveolar lamellar body membrane; IDA:UniProtKB.
DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:UniProtKB.
DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR GO; GO:0042599; C:lamellar body; IDA:UniProtKB.
DR GO; GO:0097232; C:lamellar body membrane; IDA:UniProtKB.
DR GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0032585; C:multivesicular body membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR GO; GO:0008559; F:ABC-type xenobiotic transporter activity; IMP:UniProtKB.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IBA:GO_Central.
DR GO; GO:0005319; F:lipid transporter activity; IBA:GO_Central.
DR GO; GO:0140345; F:phosphatidylcholine flippase activity; IMP:UniProtKB.
DR GO; GO:0120019; F:phosphatidylcholine transfer activity; IMP:UniProtKB.
DR GO; GO:0006869; P:lipid transport; IBA:GO_Central.
DR GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR GO; GO:0070925; P:organelle assembly; ISS:UniProtKB.
DR GO; GO:0046470; P:phosphatidylcholine metabolic process; IMP:UniProtKB.
DR GO; GO:0046471; P:phosphatidylglycerol metabolic process; ISS:UniProtKB.
DR GO; GO:0055091; P:phospholipid homeostasis; IEA:Ensembl.
DR GO; GO:0015914; P:phospholipid transport; IMP:UniProtKB.
DR GO; GO:0010875; P:positive regulation of cholesterol efflux; IMP:UniProtKB.
DR GO; GO:1902995; P:positive regulation of phospholipid efflux; IMP:UniProtKB.
DR GO; GO:2001140; P:positive regulation of phospholipid transport; IMP:UniProtKB.
DR GO; GO:0032464; P:positive regulation of protein homooligomerization; IDA:UniProtKB.
DR GO; GO:0046890; P:regulation of lipid biosynthetic process; IEA:Ensembl.
DR GO; GO:0150172; P:regulation of phosphatidylcholine metabolic process; IMP:UniProtKB.
DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR GO; GO:0009410; P:response to xenobiotic stimulus; TAS:ProtInc.
DR GO; GO:0043129; P:surfactant homeostasis; ISS:UniProtKB.
DR GO; GO:0046618; P:xenobiotic export from cell; IMP:UniProtKB.
DR GO; GO:0006855; P:xenobiotic transmembrane transport; IMP:UniProtKB.
DR GO; GO:0042908; P:xenobiotic transport; IMP:UniProtKB.
DR Gene3D; 3.40.50.300; -; 2.
DR InterPro; IPR003593; AAA+_ATPase.
DR InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR InterPro; IPR017871; ABC_transporter-like_CS.
DR InterPro; IPR026082; ABCA.
DR InterPro; IPR027417; P-loop_NTPase.
DR PANTHER; PTHR19229; PTHR19229; 1.
DR Pfam; PF00005; ABC_tran; 2.
DR SMART; SM00382; AAA; 2.
DR SUPFAM; SSF52540; SSF52540; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE 1: Evidence at protein level;
KW Alternative splicing; ATP-binding; Cytoplasmic vesicle; Disease variant;
KW Disulfide bond; Endosome; Glycoprotein; Lipid transport; Lysosome;
KW Membrane; Nucleotide-binding; Reference proteome; Repeat; Translocase;
KW Transmembrane; Transmembrane helix; Transport.
FT CHAIN 1..1704
FT /note="Phospholipid-transporting ATPase ABCA3"
FT /id="PRO_0000093293"
FT CHAIN 175..1704
FT /note="150 Kda mature form"
FT /evidence="ECO:0000305|PubMed:27031696"
FT /id="PRO_0000452297"
FT TRANSMEM 22..42
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 261..283
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 307..327
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 344..364
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 373..393
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 405..425
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 447..467
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 925..945
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1100..1120
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1144..1164
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1183..1203
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1213..1233
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1245..1265
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1306..1326
FT /note="Helical"
FT /evidence="ECO:0000255"
FT DOMAIN 530..763
FT /note="ABC transporter 1"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT DOMAIN 1381..1614
FT /note="ABC transporter 2"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT BINDING 566..573
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /ligand_label="1"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT BINDING 1416..1423
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /ligand_label="2"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT SITE 174..175
FT /note="Cleavage; by CTSL"
FT /evidence="ECO:0000269|PubMed:27031696"
FT CARBOHYD 14
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 53
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 124
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255, ECO:0000269|PubMed:24142515"
FT CARBOHYD 140
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255, ECO:0000269|PubMed:24142515"
FT CARBOHYD 620
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 783
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT VAR_SEQ 206..209
FT /note="YIRE -> EKLG (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_056262"
FT VAR_SEQ 210..1704
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_056263"
FT VARIANT 43
FT /note="R -> L (in SMDP3; unknown pathological
FT significance)"
FT /evidence="ECO:0000269|PubMed:16728712"
FT /id="VAR_084240"
FT VARIANT 101
FT /note="L -> P (in SMDP3; loss of intracellular vesicle
FT membrane location; loss of proteolytic cleavage; does not
FT affect N-glycosylation; loss of ATP hydrolysis activity;
FT decreases ATP binding in vitro; dbSNP:rs121909182)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783"
FT /id="VAR_023497"
FT VARIANT 140
FT /note="N -> H (in dbSNP:rs45447801)"
FT /evidence="ECO:0000269|Ref.4"
FT /id="VAR_025061"
FT VARIANT 215
FT /note="Q -> K (in SMDP3; loss of lamellar bodies membrane
FT location; loss of proteolytic cleavage; increases cellular
FT free cholesterol and phosphatidylcholine transport; loss of
FT vesicles formation; increases free cholesterol induced cell
FT death; loss of protein oligomerization; dbSNP:rs879159551)"
FT /evidence="ECO:0000269|PubMed:16728712,
FT ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:25817392,
FT ECO:0000269|PubMed:27352740"
FT /id="VAR_084241"
FT VARIANT 280
FT /note="R -> C (in SMDP3; unknown pathological significance;
FT does not affect protein oligomerization;
FT dbSNP:rs201299260)"
FT /evidence="ECO:0000269|PubMed:25712598,
FT ECO:0000269|PubMed:27352740"
FT /id="VAR_084242"
FT VARIANT 288
FT /note="R -> K (in SMDP3; unknown pathological significance;
FT does not affects protein oligomerization;
FT dbSNP:rs117603931)"
FT /evidence="ECO:0000269|PubMed:16728712,
FT ECO:0000269|PubMed:27352740"
FT /id="VAR_084243"
FT VARIANT 290
FT /note="L -> M (in a breast cancer sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:16959974"
FT /id="VAR_035728"
FT VARIANT 292
FT /note="E -> V (in SMDP3; unknown pathological significance;
FT does not affect lamellar bodies membrane location; does not
FT affect proteolytic cleavage; affects lamellar bodies
FT formation; does not affect cholesterol and
FT phosphatidylcholine transport; decreases vesicles
FT formation; does not affect free cholesterol induced cell
FT death; dbSNP:rs149989682)"
FT /evidence="ECO:0000269|PubMed:15976379,
FT ECO:0000269|PubMed:20863830, ECO:0000269|PubMed:25817392,
FT ECO:0000269|PubMed:28887056"
FT /id="VAR_084244"
FT VARIANT 568
FT /note="N -> D (in SMDP3; does not affect location in
FT intracellular vesicle membrane; does not affect proteolytic
FT cleavage; does not affect N-glycosylation; loss of ATP
FT hydrolysis activity; decreases ATP binding in vitro; does
FT not affect protein expression; does not affect
FT multivesicular bodies and lamellar bodies location; affects
FT multivesicular bodies and lamellar bodies development; loss
FT of phosphatidylcholine transport; does not affect
FT cholesterol transport; dbSNP:rs121909184)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:17574245,
FT ECO:0000269|PubMed:31473345"
FT /id="VAR_023498"
FT VARIANT 579
FT /note="L -> P (in SMDP3; unknown pathological
FT significance)"
FT /evidence="ECO:0000269|PubMed:16728712"
FT /id="VAR_084245"
FT VARIANT 605
FT /note="R -> Q (in SMDP3; unknown pathological significance;
FT dbSNP:rs760006956)"
FT /evidence="ECO:0000269|PubMed:16728712"
FT /id="VAR_084246"
FT VARIANT 690
FT /note="E -> K (in SMDP3)"
FT /evidence="ECO:0000269|PubMed:15976379"
FT /id="VAR_084247"
FT VARIANT 766
FT /note="P -> S (in dbSNP:rs45592239)"
FT /evidence="ECO:0000269|Ref.4"
FT /id="VAR_025062"
FT VARIANT 801
FT /note="E -> D (in a breast cancer sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:16959974"
FT /id="VAR_035729"
FT VARIANT 982
FT /note="L -> P (in SMDP3; loss of intracellular vesicle
FT membrane location; loss of proteolytic cleavage; does not
FT affect N-glycosylation; dbSNP:rs1402761450)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783"
FT /id="VAR_084248"
FT VARIANT 1069
FT /note="H -> Q (in a breast cancer sample; somatic
FT mutation)"
FT /evidence="ECO:0000269|PubMed:16959974"
FT /id="VAR_035730"
FT VARIANT 1076
FT /note="N -> K (in SMDP3; unknown pathological
FT significance)"
FT /evidence="ECO:0000269|PubMed:15976379"
FT /id="VAR_084249"
FT VARIANT 1114
FT /note="T -> M (in SMDP3; dbSNP:rs891579143)"
FT /evidence="ECO:0000269|PubMed:15976379"
FT /id="VAR_084250"
FT VARIANT 1221
FT /note="G -> S (in SMDP3; does not affect intracellular
FT vesicle membrane location; does not affect proteolytic
FT cleavage; does not affect N-glycosylation; loss of ATP
FT hydrolysis activity)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783"
FT /id="VAR_084251"
FT VARIANT 1301
FT /note="P -> L (in SMDP3; dbSNP:rs762699052)"
FT /evidence="ECO:0000269|PubMed:15976379"
FT /id="VAR_084252"
FT VARIANT 1302
FT /note="G -> E (in SMDP3; unknown pathological
FT significance)"
FT /evidence="ECO:0000269|PubMed:15976379"
FT /id="VAR_084253"
FT VARIANT 1388
FT /note="K -> N (in SMDP3; decreases phosphatidylcholine
FT transport; increases protein abundance; does not affect
FT folding in the endoplasmic reticulum; decreases proteolytic
FT processing; affects lamellar bodies development; reduces
FT free cholesterol transport)"
FT /evidence="ECO:0000269|PubMed:27177387,
FT ECO:0000269|PubMed:28887056"
FT /id="VAR_084254"
FT VARIANT 1399
FT /note="V -> M (in SMDP3; dbSNP:rs763166660)"
FT /evidence="ECO:0000269|PubMed:25712598"
FT /id="VAR_084255"
FT VARIANT 1553
FT /note="L -> P (in SMDP3; loss of intracellular vesicle
FT membrane location; loss of proteolytic cleavage; does not
FT affect N-glycosylation; dbSNP:rs121909183)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783"
FT /id="VAR_023499"
FT VARIANT 1561..1704
FT /note="Missing (in SMDP3)"
FT /evidence="ECO:0000269|PubMed:16728712"
FT /id="VAR_084256"
FT VARIANT 1580
FT /note="L -> P (in SMDP3; does not affect location in
FT intracellular vesicle membrane; does not affect proteolytic
FT cleavage; does not affect N-glycosylation; loss of ATP
FT hydrolysis activity; decreases ATP binding in vitro;
FT affects the intracellular vesicles development; decreases
FT phosphatidylcholine transport)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783, ECO:0000269|PubMed:31473345"
FT /id="VAR_084257"
FT VARIANT 1589..1704
FT /note="Missing (in SMDP3)"
FT /evidence="ECO:0000269|PubMed:25712598"
FT /id="VAR_084258"
FT VARIANT 1591
FT /note="Q -> P (in SMDP3; loss of intracellular vesicle
FT membrane location; loss of proteolytic cleavage; does not
FT affect N-glycosylation; dbSNP:rs28936691)"
FT /evidence="ECO:0000269|PubMed:15044640,
FT ECO:0000269|PubMed:16959783"
FT /id="VAR_023500"
FT MUTAGEN 53
FT /note="N->Q: Does not affect N-glycosylation. Does not
FT affect protein expression. Does not affect lamellar body
FT membrane location."
FT /evidence="ECO:0000269|PubMed:24142515"
FT MUTAGEN 124
FT /note="N->Q: Loss of N-glycosylation. Reduces protein
FT expression by 50%. Affects anterograde trafficking; when
FT associated with Q-140. Reduces protein expression by 85%;
FT when associated with Q-140. Does not affect lamellar body
FT membrane location."
FT /evidence="ECO:0000269|PubMed:24142515"
FT MUTAGEN 140
FT /note="N->Q: Loss of N-glycosylation. Reduces protein
FT expression by 50%. Affects anterograde trafficking; when
FT associated with Q-124. Reduces protein expression by 85%;
FT when associated with Q-140. Does not affect lamellar body
FT membrane location."
FT /evidence="ECO:0000269|PubMed:24142515"
FT MUTAGEN 173..174
FT /note="LK->AA: Loss of proteolytic processing."
FT /evidence="ECO:0000269|PubMed:27031696"
FT MUTAGEN 693
FT /note="S->L: Does not affect protein oligomerization."
FT /evidence="ECO:0000269|PubMed:27352740"
FT MUTAGEN 945
FT /note="N->Q: Does not affect lamellar body membrane
FT location. Does not affect protein expression. Does not
FT affect proteolytic processing."
FT /evidence="ECO:0000269|PubMed:24142515"
FT MUTAGEN 1221
FT /note="G->A: Decreases ATP hydrolysis activity of 15%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT MUTAGEN 1221
FT /note="G->T: Decreases ATP hydrolysis activity of 36%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT MUTAGEN 1221
FT /note="G->V: Decreases ATP hydrolysis activity of 18%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT MUTAGEN 1580
FT /note="L->A: Decreases ATP hydrolysis activity of 13%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT MUTAGEN 1580
FT /note="L->F: Decreases ATP hydrolysis activity of 13%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT MUTAGEN 1580
FT /note="L->V: Decreases ATP hydrolysis activity of 56%
FT compared to the wild-type."
FT /evidence="ECO:0000269|PubMed:16959783"
FT CONFLICT 36
FT /note="S -> P (in Ref. 1; AAC50967)"
FT /evidence="ECO:0000305"
FT CONFLICT 196
FT /note="P -> L (in Ref. 1; AAC50967)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 1704 AA; 191362 MW; 606735C504839D0D CRC64;
MAVLRQLALL LWKNYTLQKR KVLVTVLELF LPLLFSGILI WLRLKIQSEN VPNATIYPGQ
SIQELPLFFT FPPPGDTWEL AYIPSHSDAA KTVTETVRRA LVINMRVRGF PSEKDFEDYI
RYDNCSSSVL AAVVFEHPFN HSKEPLPLAV KYHLRFSYTR RNYMWTQTGS FFLKETEGWH
TTSLFPLFPN PGPREPTSPD GGEPGYIREG FLAVQHAVDR AIMEYHADAA TRQLFQRLTV
TIKRFPYPPF IADPFLVAIQ YQLPLLLLLS FTYTALTIAR AVVQEKERRL KEYMRMMGLS
SWLHWSAWFL LFFLFLLIAA SFMTLLFCVK VKPNVAVLSR SDPSLVLAFL LCFAISTISF
SFMVSTFFSK ANMAAAFGGF LYFFTYIPYF FVAPRYNWMT LSQKLCSCLL SNVAMAMGAQ
LIGKFEAKGM GIQWRDLLSP VNVDDDFCFG QVLGMLLLDS VLYGLVTWYM EAVFPGQFGV
PQPWYFFIMP SYWCGKPRAV AGKEEEDSDP EKALRNEYFE AEPEDLVAGI KIKHLSKVFR
VGNKDRAAVR DLNLNLYEGQ ITVLLGHNGA GKTTTLSMLT GLFPPTSGRA YISGYEISQD
MVQIRKSLGL CPQHDILFDN LTVAEHLYFY AQLKGLSRQK CPEEVKQMLH IIGLEDKWNS
RSRFLSGGMR RKLSIGIALI AGSKVLILDE PTSGMDAISR RAIWDLLQRQ KSDRTIVLTT
HFMDEADLLG DRIAIMAKGE LQCCGSSLFL KQKYGAGYHM TLVKEPHCNP EDISQLVHHH
VPNATLESSA GAELSFILPR ESTHRFEGLF AKLEKKQKEL GIASFGASIT TMEEVFLRVG
KLVDSSMDIQ AIQLPALQYQ HERRASDWAV DSNLCGAMDP SDGIGALIEE ERTAVKLNTG
LALHCQQFWA MFLKKAAYSW REWKMVAAQV LVPLTCVTLA LLAINYSSEL FDDPMLRLTL
GEYGRTVVPF SVPGTSQLGQ QLSEHLKDAL QAEGQEPREV LGDLEEFLIF RASVEGGGFN
ERCLVAASFR DVGERTVVNA LFNNQAYHSP ATALAVVDNL LFKLLCGPHA SIVVSNFPQP
RSALQAAKDQ FNEGRKGFDI ALNLLFAMAF LASTFSILAV SERAVQAKHV QFVSGVHVAS
FWLSALLWDL ISFLIPSLLL LVVFKAFDVR AFTRDGHMAD TLLLLLLYGW AIIPLMYLMN
FFFLGAATAY TRLTIFNILS GIATFLMVTI MRIPAVKLEE LSKTLDHVFL VLPNHCLGMA
VSSFYENYET RRYCTSSEVA AHYCKKYNIQ YQENFYAWSA PGVGRFVASM AASGCAYLIL
LFLIETNLLQ RLRGILCALR RRRTLTELYT RMPVLPEDQD VADERTRILA PSPDSLLHTP
LIIKELSKVY EQRVPLLAVD RLSLAVQKGE CFGLLGFNGA GKTTTFKMLT GEESLTSGDA
FVGGHRISSD VGKVRQRIGY CPQFDALLDH MTGREMLVMY ARLRGIPERH IGACVENTLR
GLLLEPHANK LVRTYSGGNK RKLSTGIALI GEPAVIFLDE PSTGMDPVAR RLLWDTVARA
RESGKAIIIT SHSMEECEAL CTRLAIMVQG QFKCLGSPQH LKSKFGSGYS LRAKVQSEGQ
QEALEEFKAF VDLTFPGSVL EDEHQGMVHY HLPGRDLSWA KVFGILEKAK EKYGVDDYSV
SQISLEQVFL SFAHLQPPTA EEGR
